Seminal Trials: IPASS for EGFR NSCLC

Episode
142
Soundcloud
Share

In this special episode of Lung Cancer Considered, hosts Dr. Stephen Liu and Dr. Narjust Florez discuss the seminal IPASS trial with its principal investigator, Dr. Tony Mok. IPASS was a randomized phase III trial that compared the EGFR TKI gefitinib to carboplatin plus paclitaxel and showed, for the first time, that in a selected population, targeted therapy was superior to chemotherapy. The initial results were published in the New England Journal of Medicine in 2009 and helped usher in the era of precision oncology. Dr. Tony Mok is the Li Shu Fan Medical Foundation Endowed Professor and Chairman of the Department of Clinical Oncology at the Chinese University of Hong Kong. He co-founded the Lung Cancer Research Group, Chinese Thoracic Oncology Research Group, and Asia Thoracic Oncology Research Group.

Guest
Stephen Liu
Stephen Liu

MD

Associate Professor of Medicine, Director of Thoracic Oncology and Director of Developmental Therapeutics
Georgetown Lombardi Comprehensive Cancer Center
Narjust Florez
Narjust Florez

MD

Associate Director of the Cancer Care Equity Program and Assistant Professor of Medicine
Dana-Farber Cancer Institute
Harvard Medical School
Dr. Tony Mok
Dr. Tony Mok

MD, FRCP

Professor of Clinical Oncology
The Chinese Univ. of Hong Kong
Li Shu Fan Medical Foundation

Other Podcast